What is thymosin alpha-1?
FDA's December 2024 briefing describes thymosin alpha-1 as an N-terminal-acetylated peptide containing 28 amino acids. This is a chemical description of the evaluated material. The Thymosin Alpha-1 vial is listed as 10mg, but its name and amount do not independently verify that formulation or establish a clinical effect. FDA thymosin-alpha-1 assessment.
The clinical question is more specific than an immune-boosting phrase. A large randomized trial examined a defined outcome in adults with sepsis, allowing its result to be stated in disease- and endpoint-specific terms. TESTS sepsis trial.
TESTS trial and corrected mortality result
The 2025 phase 3 TESTS trial randomized 1,106 adults with sepsis to thymosin-alpha1 or placebo. The investigators concluded that it found no clear evidence of reduced 28-day mortality in that population. This is a sepsis mortality result, rather than a general assessment of all immune functions. TESTS sepsis trial.
The published correction gives the hazard ratio for 28-day mortality as 0.97, with a 95% confidence interval of 0.76 to 1.24. The numbers concern the trial's mortality comparison, not the supplier vial. Published correction, TESTS sepsis trial.
Compounded thymosin alpha-1 safety concerns
FDA identifies peptide-characterization and potential immune-response concerns for compounded thymosin-alpha-1. It also states that available safety information is inadequate to understand the extent of safety issues raised by the proposed compounded drug. Inadequate safety information is not a finding that the product is safe. FDA compounding safety communication.
The sepsis trial and the FDA communication have different scopes: one reports a specified clinical comparison, while the other addresses safety information for a proposed compounded drug. Neither authenticates the catalogue vial or establishes a broad immune benefit for it. TESTS sepsis trial, FDA compounding safety communication.
The separate Thymosin Alpha-1 10mg Pen can be compared by its documented presentation. A shared amount does not establish matching formulation or transfer the trial result to either supplier item. TESTS sepsis trial.
